

Interferon gamma causes olfactory dysfunction without concomitant neuroepithelial damage

Tatyana Pozharskaya, MS and Andrew P. Lane, MD

Background: Olfactory loss is a debilitating symptom of chronic rhinosinusitis (CRS). The pathophysiology of inflammatory olfactory dysfunction likely involves both conductive and sensorineural components. To study the interaction of CRS-associated inflammatory cytokines with the olfactory epithelium (OE), a transgenic mouse model was developed that allows temporally-controlled local gene expression. Interferon-gamma (IFN- γ) is a prototypical T helper 1 (Th1) cytokine linked to nonpolypoid CRS (CRSsNP), as well as sinonasal viral and bacterial infections. In this study, the effects of chronic IFN- γ expression on olfactory histology and function were investigated.

Methods: IFN- γ secretion by olfactory sustentacular cells was induced in the transgenic mouse. Viability and gross behavior were unaffected. Mice were euthanized after 6 weeks of IFN- γ expression, and olfactory tissue was studied by histology, immunohistochemistry, and electro-olfactography (EOG). Findings were compared with uninduced littermates.

Results: IFN- γ expression did not result in alteration of the normal histologic architecture of the neuroepithelium

or lamina propria. However, EOG recordings demonstrated a significant decrease in odorant responses after IFN- γ expression. In addition, a marked increase in submucosal CD45-positive cells was observed, the majority of which were CD3-positive and CD4-positive lymphocytes.

Conclusion: Chronic IFN- γ expression in the mouse OE results in diminished odorant responsiveness, despite the absence of inflammatory tissue damage. This suggests a direct effect of IFN- γ on olfactory neuron function that may underlie olfactory loss in CRSsNP or viral infections. The infiltration of submucosal lymphocytes raises the possibility that other downstream cytokines also contribute to olfactory dysfunction. © 2013 ARS-AAOA, LLC.

Key Words:

olfactory loss; rhinosinusitis; interferon gamma; transgenic model

How to Cite this Article:

Pozharskaya T, Lane AP. Interferon gamma causes olfactory dysfunction without concomitant neuroepithelial damage. *Int Forum Allergy Rhinol.* 2013;3:861-865.

Olfactory dysfunction is an often underappreciated symptom of chronic rhinosinusitis (CRS) that has a particularly negative impact on quality of life.¹⁻³ The mechanisms underlying the loss of the sense of smell in CRS are incompletely understood, but appear to be more complex than simple airflow obstruction to the olfactory

cleft. Most likely, pathologic alterations in peripheral olfactory structure and physiology due to chronic inflammation play a significant role.⁴ The olfactory neuroepithelium resides at an important immunological barrier within the nasal cavity and is in contact with the external environment; it is thus vulnerable to both exogenous injury and endogenous host defensive processes.⁵ Fortunately, olfactory neurons and their progenitors are resilient and have a remarkable capacity for regeneration that is unique within the nervous system. This capacity for regeneration may not be unlimited, however, and it is believed that longstanding tissue damage ultimately results in replacement of the specialized olfactory neuroepithelium with respiratory mucosa, leading to permanent dysfunction.⁴ That being said, even when olfactory epithelium (OE) integrity is maintained, patients with CRS may experience waxing and waning olfactory dysfunction that is relatively rapidly reversed with systemic corticosteroids. These properties suggest that

Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD

Correspondence to: Andrew P. Lane, MD, Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Outpatient Center, 601 N. Caroline St; 6th floor; 6250, Baltimore, MD 21287-0910; e-mail: alane3@jhmi.edu

Funding sources for the study: National Institute on Deafness and Other Communicative Disorders (NIDCD) NIH (DC009026 to A.P.L.). Potential conflict of interest: None provided.

Presented orally at the Annual ARS Meeting on September 8, 2012, Washington, DC.

Received: 13 March 2013; Revised: 19 July 2013, 1 August 2013
DOI: 10.1002/alar.21226

View this article online at wileyonlinelibrary.com.

mechanisms other than tissue damage, perhaps related to local cytokine-mediated inflammation, contribute to olfactory dysfunction.

In order to study the role of cytokines in human CRS-associated olfactory loss, a transgenic mouse model was developed in which olfactory sustentacular cells can be induced to express inflammatory cytokines.^{6–9} Initial studies with the inducible olfactory inflammation (IOI) model demonstrated that expression of the CRS-associated cytokine, tumor necrosis factor alpha (TNF- α), resulted in a progressive inflammatory infiltrate that mimicked aspects of mucosal inflammation in CRS, including an inflammatory cell infiltrate and a downstream cascade of other cytokine mediators described in CRS. TNF- α -induced chronic olfactory inflammation is characterized by progressive neuronal apoptosis, suppression of normal olfactory regeneration, and decreased electrophysiologic response to odorants.^{6,8} The decrease in electrical olfactory responses occurs weeks prior to the neuronal loss, suggesting a functional effect of inflammation on intact neurons. Moreover, although systemic corticosteroids improve the degree of olfactory inflammation in the IOI(TNF- α) mouse, odorant responses remain diminished.⁹ This finding supports previous *in vitro* evidence that TNF- α has direct effects on olfactory neurons and their progenitors.^{10,11}

In recent years, an ever-expanding number of cytokines have been identified in the sinonasal mucosa, both in health and disease. There is no universal mediator profile associated with CRS, but the clinical categorization of CRS based on the presence or absence of nasal polyps (CR-SwNP and CRSsNP, respectively) allows differentiation on the basis of T helper 2 (Th2) cytokines. Specifically, whereas both forms of CRS are associated with Th1-type inflammatory mediators, CRSwNP is distinguished by a mixed profile that prominently includes Th2 cytokines. Interferon gamma (IFN- γ) is the prototypical Th1 cytokine, and its expression in the sinonasal tract is well established.^{12–14} As the sole type II interferon, IFN- γ has diverse roles in orchestrating immune system function during infection. It modulates the inflammatory state by synergizing or antagonizing the effects of other cytokines, growth factors, and innate immune pattern-recognition receptors. In addition to key roles driving sinonasal mucosal immune responses to rhinoviruses,¹⁵ IFN- γ expression has been linked to the immune response to sinonasal biofilms.¹⁶

The loss of the sense of smell in CRS is extremely prevalent in CRSwNP, but also occurs with significant frequency in CRSsNP.^{17,18} Given that Th1 inflammation is common to both forms of CRS, it is reasonable to postulate that IFN- γ -mediated cytokine pathways may play a role in the pathogenesis of CRS-associated olfactory loss. In this study, we used the IOI mouse model to investigate the impact of chronic IFN- γ expression on the structure and function of the OE.

Materials and methods

IOI INF- γ mouse

The creation of the IOI mouse line has been described previously.⁶ Briefly, the reverse tetracycline transactivator gene (rtTA) was knocked into the olfactory-specific *cyp2g1* coding region generating a *cyp2g1*-rtTA strain. This line was crossed with a line containing the INF- γ gene under the control of a tetracycline-responsive element (TRE-INF- γ) (The Jackson Laboratory, Bar Harbor, ME) to generate the inducible inflammation model IOI(INF- γ). Doxycycline (DOX) was used to induce INF- γ expression in adult mice between 6 and 8 weeks old.

Histologic analysis

After euthanasia by CO₂ inhalation, the mice were decapitated and the heads were fixed and decalcified by immersion in TBD2 decalcifying solution (Shandon, Pittsburgh, PA) for 24 hours. The heads were embedded in paraffin, and 6- μ m sections were obtained and collected on glass slides for hematoxylin and eosin staining. For frozen section analysis, the mice were anesthetized by an intraperitoneal injection of 100 mg/kg of ketamine hydrochloride/xylazine hydrochloride solution (Sigma, St. Louis, MO) before intracardiac perfusion with 4% paraformaldehyde. The olfactory tissue was then dissected, postfixed in 4% paraformaldehyde overnight, and transferred to a solution of 30% sucrose and 250 mM of ethylenediamine tetraacetic acid (EDTA) for 48 hours. The decalcified heads were then infiltrated with TFM tissue freezing medium (Triangle Biomedical Sciences, Inc., Durham, NC) and frozen on dry ice into a plastic mold. Sections of mouse olfactory tissue in OCT were cut on a cryostat (12 μ m), placed on Superfrost plus slides (Fisher Scientific, Pittsburgh, PA), and dried at 4°C overnight. Slides were stored at –80°C for future staining.

Immunohistochemistry

Cryostat sections were washed in phosphate-buffered saline (PBS) and were blocked for 1 hour in PBS containing 10% normal goat serum. Slides were incubated overnight at 4°C in 5% normal serum containing primary antibody to CD45 (1:100; eBiosciences, San Diego, CA; #14-0451), anti-mouse CD3 (1:100; eBiosciences; #14-0032), and anti-mouse CD4 (1:100; eBiosciences; #14-0041), and neural cell adhesion molecules (NCAMs) (1:1000; Millipore, Billerica, MA). For anti-keratin 5 staining (1:500; Covance, Princeton, NJ), an antigen retrieval step was performed prior to washing: slides were microwaved at 60% power (1000 MW) for 10 minutes in 0.01 M Citrate Buffer, pH 6.0. Primary antibodies were detected using 1:200 dilution of fluorescent-tagged secondary antibodies (Alexa-Fluor; Invitrogen, Carlsbad, CA; and Dylight; Jackson ImmunoResearch, West Grove, PA). Each sample was counterstained by the nuclear stain, 4',6-diamidino-2-phenylindole (DAPI) (Vector Labs, Burlingame, CA).

Z-stack images were obtained using a LSM510 confocal microscope (Carl Zeiss Micro-imaging, Thornwood, NY). Measurements of relative area coverage and cell counts were performed using ImageJ 1.46 software (NIH, Bethesda, MD).

Bromodeoxyuridine labeling

Mice were injected intraperitoneally with bromodeoxyuridine (BrdU) (Sigma, St. Louis, MO), 50 $\mu\text{g/g}$ of body weight, 2 hours before euthanasia. Cryostat sections were then incubated with 3 N HCl for 30 minutes and treated with proteinase K in Tris-EDTA buffer for 10 minutes before immunostaining with rat anti-BrdU antibody (1:100; Abcam, Cambridge, MA). Primary antibodies were detected using a fluorescent-tagged secondary antibody (Alexa-Fluor). Each sample was counterstained by DAPI. Images were collected using a LSM510 confocal microscope.

Electro-olfactography

Electro-olfactography (EOG) was performed according to published methods.^{6,7,9} The medial surface of the olfactory turbinates was prepared for recording after the mouse was euthanized using CO₂. Odorant solutions (Sigma-Aldrich, St. Louis, MO) were prepared in dimethyl sulfoxide (DMSO) and diluted with water to the working concentration just before EOG recording. Test odorants for air delivery were prepared at liquid concentrations of 10⁻³ (final DMSO concentration of 0.2% vol/vol), and diluted to 10⁻⁴ and 10⁻⁵ M concentrations. Responses to DMSO diluent alone were measured. Odorant stimulation was delivered in the vapor phase as a 100-ms pulse by injection into the continuous stream of humidified air. The odorant stimulus pathway was cleaned by air between each stimulus presentation with a minimum interval of 1 minute between 2 adjacent stimuli. Field potentials were measured with 2 electrodes, placed on either turbinate IIb or turbinate III, to acquire simultaneous recordings. Data was analyzed with Clampfit (Axon Instruments, Union City, CA). Peak amplitudes were determined from prepulse baseline, but no other data normalizations were performed.

Quantification of IFN- γ expression

Nasal lavage fluid was collected by perfusing 250 μL of PBS over the bisected nasal cavity. The fluid was stored at 80°C for subsequent analysis. IFN- γ was quantified using an enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions (R&D Systems).

Statistical analysis

Raw data was entered into spreadsheet software for statistical analysis (Excel; Microsoft Corp, Redmond, WA). Data are expressed as mean $\pm$ standard error of the mean (SEM). Statistical comparisons between wild-type and IOI(IFN- γ) mice were performed using 2-tailed *t* tests. Differences were considered to be statistically significant at *p* < 0.05.

Results

In the absence of inflammation, the OE demonstrates an apical single layer of sustentacular cells overlying a densely packed layer of olfactory sensory neurons and their progenitors (Fig. 1, top left panel). Multipotent stem cells (horizontal basal cells and globose cells) reside in the most basal aspect of the neuronal layer. Below the basement membrane in the subepithelium are well-demarcated axon bundles. In the absence of DOX administration, the olfactory histologic phenotypes of IOI(IFN- γ) mice are identically normal. After 6 weeks of DOX induction, IFN- γ is highly expressed and detectable in nasal lavage fluid (Fig. 1C). TNF- α was undetectable in the lavage fluid by ELISA (data not shown). At this time point in the IOI(IFN- γ) mice, the OE remains intact and grossly normal in appearance, with intact sustentacular cells and neuron layer (Fig. 1A). In the subepithelium, there is disruption in the architecture, with inflammatory cell infiltration and compression of the axon bundles, which is more evident in the higher magnification images. To better visualize the changes suggested by the histologic sections, immunohistochemical staining was performed to visualize olfactory neurons and their axon bundles with an antibody to NCAMs (Fig. 1B). In the absence of inflammation, NCAM is highly expressed in the cytoplasm of the olfactory neurons within the OE and in the axon bundles within the subepithelium. NCAM staining remains normal after 6 weeks of IFN- γ expression, although the axons bundles appear distorted by the subepithelial inflammatory infiltrate.

An antibody to the CD45 common leukocyte antigen¹⁹ was used to visualize nucleated cells of hematopoietic origin within the olfactory turbinate, to better demarcate the inflammatory cell infiltrate (Fig. 2). The pattern of antibody staining for K5, a marker of progenitor horizontal basal cells, and for BrdU, a marker used for demonstrating cell proliferation, were both unchanged between control and IOI(IFN- γ) mice (data not shown).

The effect of IFN- γ on sensory function was assessed by EOG recordings (Fig. 3). After 6 weeks of DOX administration, odorant responses in the IOI(IFN- γ) mouse were significantly reduced, to an average amplitude 40% to 60% that of control.

Discussion

In the present study, we show that chronic expression of IFN- γ in the mouse OE results in prominent lymphocytic inflammation, without the progressive loss of olfactory neurons that is seen when TNF- α is similarly expressed. Despite the preservation of a histologically intact olfactory neuron layer, a significant decrease in electrophysiologic responses to odorants is observed in the IOI(IFN- γ) mouse. This finding provides additional support to the concept that the steroid-sensitive hyposmia in CRS patients may relate to direct effects of CRS-associated inflammatory cytokines on olfactory neuron function.




FIGURE 1. (A) Hematoxylin and eosin staining of the olfactory epithelium in control (left) and IFN- γ mice (right), after 6 weeks DOX induction. Upper panels $\times 20$. Lower panels $\times 40$. Scale bar = 25 μm . (B) NCAM immunostaining in control (left) and IFN- γ mice (right) after 6 weeks of DOX induction. Blue staining is the nuclear marker DAPI. Scale bar = 50 μm ; (C) IFN- γ levels in the nasal lavage fluid after DOX induction as determined by ELISA. IFN- γ = interferon gamma; DOX = doxycycline; NCAM = neural cell adhesion molecule; DAPI = 4',6-diamidino-2-phenylindole; ELISA = enzyme-linked immunosorbent assay.

The observation that significant phenotypic differences exist between chronic olfactory inflammation induced by IFN- γ and by TNF- α is potentially informative. Further characterization and comparison of inflammatory infiltrate




FIGURE 2. Immunostaining of control (top left) and IFN- γ mice (top right) for the common leukocyte antigen CD45, which labels nucleated hematopoietic cells. Bottom: Percentage of turbinate area immunolabeled for CD45, CD3, and CD4 in control vs IFN- γ mice. $n = 3$ mice per group. $*p < 0.05$. IFN- γ = interferon gamma.




FIGURE 3. Electro-olfactogram quantification of odorant responses in control and IOI(IFN- γ) mice after 6 weeks DOX induction. Results expressed as the mean of 4 separate EOG recordings from each group. $*p < 0.05$. AA = amyl acetate; AP = acetophenone; IOI = inducible olfactory inflammation; IFN- γ = interferon gamma; DOX = doxycycline.

compositions and resulting cytokine profiles may help explain the differential effects on neurons and progenitor populations. Future studies making use of systemic corticosteroids to inhibit cytokine gene expression downstream of IFN- γ may help differentiate indirect effects of IFN- γ on

olfactory neuron function. Similarly, conditional knockout mice in which the IFN- γ receptor is absent on olfactory neurons can be generated and used to provide additional evidence for a direct effect of IFN- γ on this cell population. By contrasting the consequences of different initiating cytokines in the IOI model, common pathways may emerge that provide a mechanism of interference with odorant signal transduction in neurons.

The role of IFN- γ in the olfactory system has not previously been explored in any in vitro or in vivo model system. Given the clinical entity of postviral anosmia and the central function of IFN- γ in antiviral immunity, a relationship between IFN signaling and olfactory dysfunction is intriguing. Such an interaction may be suggested by reports of anosmia induced by IFN therapy for hepatitis C.^{20–22} Although the presence of IFN- γ in the human OE has not been investigated, it is likely that local production of IFNs is critical to host defense against entry of neurotropic viruses, such as influenza A and herpes simplex viruses. For this reason, any treatment strategy for olfactory loss that might involve antagonism of interferons in this tissue must be considered carefully.

At present, much remains unknown about the cause of human inflammation-associated olfactory dysfunction. In part, this stems from the relative inaccessibility of the olfactory cleft and the difficulty of repeatedly obtaining sufficient quantities of biopsy samples from individual subjects. The IOI transgenic mouse model greatly facilitates investigation of cellular and molecular pathways that would be nearly impossible to explore in human subjects. With this genetic approach, individual cytokines or a combination of cytokines can be expressed in a temporally-controlled fashion in order to dissect the web of overlapping signaling pathways that interact between coexisting populations of immune cells and sensory neurons within the nasal cavity. Because CRS is a complex and multifactorial disease that is already in progress at the time of presentation, models such as the IOI mouse are necessary to study specific me-

diators in isolation and to view events that occur at the initial stages of olfactory inflammation or during its resolution. Moreover, powerful genetic tools available in mice, such as knockout strains and gene reporter constructs, can be leveraged to further elucidate mechanisms and refine pathophysiologic hypotheses.

Olfactory loss in the setting of CRS is a frustrating problem that patients often find particularly disabling. Systemic steroids reduce inflammation and may transiently improve olfaction,²³ but the benefit of the long-term use of these agents is outweighed by the risks of significant health complications. Although endoscopic sinus surgery is highly successful in improving the symptoms of CRS and allows for more effective delivery of topical anti-inflammatory agents, there is limited demonstrated benefit of surgery in improving olfaction.²⁴ Given time, it is hoped that basic research in model systems may inform development of novel therapies targeting key inflammatory signaling pathways, which potentially interact with olfactory transduction mechanisms to cause sensory neuron dysfunction in CRS.

Conclusion

The IOI transgenic mouse provides a unique model to study mechanisms underlying human olfactory dysfunction. IFN- γ is the prototypical Th1 cytokine, associated with sinonasal inflammation in CRS, particularly in the setting of infection. Chronic expression of IFN- γ in the OE initiates a local inflammatory state and diminished olfactory function. Unlike the inflammation induced by TNF- α , the expression of IFN- γ does not result in the death of olfactory neurons or the inhibition neurogenesis. This provides further evidence that inflammatory cytokines may interact directly with olfactory neurons to decrease their odorant responsiveness. Further studies are needed to fully elucidate the complex interplay between the immune system and the OE in animal models and ultimately in CRS patients. Ⓢ

References

- Hummel T, Nordin S. Olfactory disorders and their consequences for quality of life. *Acta Otolaryngol.* 2005;125:116–121.
- Seo HS, Jeon KJ, Hummel T, Min BC. Influences of olfactory impairment on depression, cognitive performance, and quality of life in Korean elderly. *Eur Arch Otorhinolaryngol.* 2009;266:1739–1745.
- Wrobel BB, Leopold DA. Olfactory and sensory attributes of the nose. *Otolaryngol Clin North Am.* 2005;38:1163–1170.
- Doty RL, Mishra A. Olfaction and its alteration by nasal obstruction, rhinitis, and rhinosinusitis. *Laryngoscope.* 2001;111:409–423.
- Doty RL. The olfactory system and its disorders. *Semin Neurol.* 2009;29:74–81.
- Lane AP, Turner J, May L, Reed R. A genetic model of chronic rhinosinusitis-associated olfactory inflammation reveals reversible functional impairment and dramatic neuroepithelial reorganization. *J Neurosci.* 2010;30:2324–2329.
- Turner JH, Liang KL, May L, Lane AP. Tumor necrosis factor alpha inhibits olfactory regeneration in a transgenic model of chronic rhinosinusitis-associated olfactory loss. *Am J Rhinol Allergy.* 2010;24:336–340.
- Turner JH, May L, Reed RR, Lane AP. Reversible loss of neuronal marker protein expression in a transgenic mouse model for sinusitis-associated olfactory dysfunction. *Am J Rhinol Allergy.* 2010;24:192–196.
- Sultan B, May LA, Lane AP. The role of TNF- α in inflammatory olfactory loss. *Laryngoscope.* 2011;121:2481–2486.
- Farbman AI, Buchholz JA, Suzuki Y, Coines A, Speert D. A molecular basis of cell death in olfactory epithelium. *J Comp Neurol.* 1999;414:306–314.
- Suzuki Y, Farbman AI. Tumor necrosis factor- α -induced apoptosis in olfactory epithelium in vitro: possible roles of caspase 1 (ICE), caspase 2 (ICH-1), and caspase 3 (CPP32). *Exp Neurol.* 2000;165:35–45.
- Otto BA, Wenzel SE. The role of cytokines in chronic rhinosinusitis with nasal polyps. *Curr Opin Otolaryngol Head Neck Surg.* 2008;16:270–274.
- Cho KS, Kim CS, Lee HS, Seo SK, Park HY, Roh HJ. Role of interferon- γ -producing t cells in the pathogenesis of chronic rhinosinusitis with nasal polyps associated with staphylococcal superantigen. *J Otolaryngol Head Neck Surg.* 2010;39:600–605.
- Han JK. Subclassification of chronic rhinosinusitis. *Laryngoscope.* 2013;123(Suppl 2):S15–S27.
- Jornot L, Cordey S, Caruso A, et al. T lymphocytes promote the antiviral and inflammatory responses of airway epithelial cells. *PLoS One.* 2011;6:e26293.
- Hekiart AM, Kofonow JM, Doghrami L, et al. Biofilms correlate with TH1 inflammation in the sinonasal tissue of patients with chronic rhinosinusitis. *Otolaryngol Head Neck Surg.* 2009;141:448–453.
- Dietz de Loos DA, Hopkins C, Fokkens WJ. Symptoms in chronic rhinosinusitis with and without nasal polyps. *Laryngoscope.* 2012;123:57–63.
- Mori E, Matsuwaki Y, Mitsuyama C, Okushi T, Nakajima T, Moriyama H. Risk factors for olfactory dysfunction in chronic rhinosinusitis. *Auris Nasus Larynx.* 2013;40:465–469.
- Dahlke MH, Larsen SR, Rasko JE, Schlitt HJ. The biology of CD45 and its use as a therapeutic target. *Leuk Lymphoma.* 2004;45:229–236.
- Cocquyt VF, Van Belle SJ. Anosmia associated with alpha-interferon treatment. *Ann Oncol.* 1994;5:863.
- Kraus I, Vitezic D. Anosmia induced with alpha interferon in a patient with chronic hepatitis C. *Int J Clin Pharmacol Ther.* 2000;38:360–361.
- Maruyama S, Hirayama C, Kadowaki Y, Sagayama A, Omura H, Nakamoto M. Interferon-induced anosmia in a patient with chronic hepatitis C. *Am J Gastroenterol.* 1998;93:122–123.
- Stevens MH. Steroid-dependent anosmia. *Laryngoscope.* 2001;111:200–203.
- Jiang RS, Lu FJ, Liang KL, et al. Olfactory function in patients with chronic rhinosinusitis before and after functional endoscopic sinus surgery. *Am J Rhinol.* 2008;22:445–448.